|
1) Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009; 361: 2548-56
|
|
|
|
2) Abela JE, Going JJ, Mackenzie JF, et al. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol. 2008; 103: 850-5
|
|
|
|
|
|
3) Wolfsen HC, Crook JE, Krishna M, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus. Gastroenterology. 2008; 135: 24-31
|
|
|
|
|
|
4) Borovicka J, Fischer J, Neuweiler J, et al. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy. Endoscopy. 2006; 38: 867-72
|
|
|
|
|
|
5) Galmiche JP, Sacher-Huvelin S, Coron E, et al. Screening for esophagitis and Barrett's esophagus with wireless esophageal capsule endoscopy: a multicenter prospective trial in patients with reflux symptoms. Am J Gastroenterol. 2008; 103: 538-45
|
|
|
|
|
|
6) Konda VJ, Chennat JS, Hart J, et al. Confocal laser endomicroscopy: potential in the management of Barrett's esophagus. Dis Esophagus. 2010; 23: E21-31
|
|
|
|
|
|
7) Kiesslich R, Canto MI. Confocal laser endomicroscopy. Gastrointest Endosc Clin N Am. 2009; 19: 261-72
|
|
|
|
|
|
8) Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340: 825-31
|
|
|
|
|
|
9) Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol. 2009; 104: 1356-62
|
|
|
|
|
|
10) Prasad GA, Bansal A, Sharma P, et al. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol. 2010; 105: 1490-502
|
|
|
|
|
|
11) Ford AC, Forman D, Reynolds PD, et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol. 2005; 162: 454-60
|
|
|
|
|
|
12) Anandasabapathy S, Jhamb J, Davila M, et al. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer. 2007; 109: 668-74
|
|
|
|
|
|
13) Jacobson BC, Chan AT, Giovannucci EL, et al. Body mass index and Barrett's oesophagus in women. Gut. 2009; 58: 1460-6
|
|
|
|
|
|
14) Edelstein ZR, Bronner MP, Rosen SN, et al. Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol. 2009; 104: 834-42
|
|
|
|
|
|
15) Musana AK, Resnick JM, Torbey CF, et al. Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol. 2008; 103: 516-24
|
|
|
|
|
|
16) Matsuzaki J, Suzuki H, Asakura K, et al. Etiological difference between ultrashort and short-segment Barrett's esophagus. J Gastroenterol. 2010 (in press)
|
|
|
|
|
|
17) Prasad GA, Bansal A, Sharma P, et al. Predictors of progression in Barrett's esophagus: carrent knowledge and future directions. Am J Gastroenterol. 2010; 105: 1490-502
|
|
|
|
|
|
18) Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol. 2009; 104: 492-500; quiz 491, 501
|
|
|
|
|
|
19) Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-81
|
|
|
|
|
|
20) Badreddine RJ, Wang KK. Barrett esophagus: an update. Nat Rev Gastroenterol Hepatol. 2010; 7: 369-78
|
|
|
|
|
|
21) Koek GH, Sifrim D, Lerut T, et al. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. Gut. 2008; 57: 1056-64
|
|
|
|
|
|
22) Izbeki F, Rosztoczy AI, Yobuta JS, et al. Increased prevalence of gallstone disease and impaired gallbladder motility in patients with Barrett's esophagus. Dig Dis Sci. 2008; 53: 2268-75
|
|
|
|
|
|
23) Matsuzaki J, Suzuki H, Asakura K, et al. Gallstones increase the prevalence of Barrett's esophagus. J Gastroenterol. 2010; 45: 171-8
|
|
|
|
|
|
24) Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998; 7: 97-102
|
|
|
|
|
|
25) Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009; 100: 551-7
|
|
|
|
|
|
26) Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001; 96: 990-6
|
|
|
|
|
|
27) Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007; 99: 545-57
|
|
|
|
|
|
28) El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004; 99: 1877-83
|
|
|
|
|
|
29) Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust. 2004; 180: 387-91
|
|
|
|
|
|
30) de Jonge PJ, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2006; 101: 1421-9
|
|
|
|
|
|
31) Islami F, Kamangar F, Boffetta P. Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am J Gastroenterol. 2009; 104: 2646-8
|
|
|
|
|
|
32) Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006; 55: 1538-44
|
|
|
|
|
|
33) Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009; 181: 161-9
|
|
|
|
|
|
34) Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus？ A meta-analysis. Am J Gastroenterol. 2003; 98: 2390-4
|
|
|
|
|
|
35) Wang VS, Hornick JL, Sepulveda JA, et al. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc. 2009; 69: 777-83
|
|
|
|
|
|
36) Sanchez A, Reza M, Blasco JA, et al. Effectiveness, safety, and cost-effectiveness of photodynamic therapy in Barrett's esophagus: a systematic review. Dis Esophagus. 2010; [Epub ahead of print]
|
|
|
|
|
|
37) Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007; 66: 460-8
|
|
|
|
|
|
38) Wolfsen HC, Hemminger LL, Wallace MB, et al. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther. 2004; 20: 1125-31
|
|
|
|
|
|
39) Prasad GA, Wang KK, Buttar NS, et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2007; 65: 60-6
|
|
|
|
|
|
40) Rees JR, Lao-Sirieix P, Wong A, et al. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev. 2010: CD004060
|
|
|
|
|
|
41) Lyday WD, Corbett FS, Kuperman DA, et al. Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010; 42: 272-8
|
|
|
|
|
|
42) Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2. 5-year follow-up. Gastrointest Endosc. 2008; 68: 867-76
|
|
|
|
|
|
43) Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci. 2010; 55: 1918-31
|
|
|
|
|
|
44) Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology. 2009; 136: 2101-14, e1-6
|
|
|
|
|